Clinical trials: Kidney Neoplasm
Renal Cell Cancer
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments in 20 evaluable patients with metastatic renal cell cancer (RCC) and an early post therapy assessment at baseline and at various early time…
- Trial name
- NCT00694096
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Renal Cell Carcinoma
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before.
- Trial name
- SUNIKA (NCT00460798)
- Testing
- Sutent: observational study
- Volunteers
- 356 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo.
- Trial name
- COSMIC-313 (NCT03937219)
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 159 sites in United States, Argentina and 23 more
- Volunteers
- 855 people
- Sponsor
- Exelixis
Kidney Cancer
Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
The goal of this clinical research is to learn how effective an ultrasound contrast agent, called DEFINITY, is when used during ultrasound-guided surgery to remove part of one or both kidneys.
- Trial name
- NCT01894607
- Testing
- Contrast Enhanced Intraoperative Ultrasound, DEFINITY, Phone Call
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®.
- Trial name
- NCT00684645
- Testing
- SUTENT
- Where
- 20 sites in Czechia
- Volunteers
- 186 people
- Sponsor
- Pfizer
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
Kidney Cancer
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells.
- Trial name
- NCT00085436
- Testing
- Aldesleukin,, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Renal Cell Cancer
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
This single arm study will assess the efficacy and safety of Avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer.
- Trial name
- NCT00520403
- Testing
- bevacizumab [Avastin], Interferon alfa-2a, Vinblastine
- Where
- 16 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Metastatic Cancer, Metastatic Renal Cancer
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Background: MAGE-A3/12 is a type of protein commonly found on certain types of cancer cells, particularly in metastatic cancer. Researchers have developed a process to take lymphocytes (white blood cells) from cancer patients…
- Conditions
- Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
- Trial name
- NCT01273181
- Testing
- PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma
- Trial name
- NCT00831844
- Testing
- cixutumumab, laboratory biomarker analysis
- Where
- 105 sites in United States, Australia and 1 more
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Renal Cell Carcinoma
Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
The purpose of this study is to know about the quality of life of patients with metastatic renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who suffer from fatigue and hand-foot syndrome…
- Trial name
- TROYA (NCT02789137)
- Where
- 23 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Kidney Cancer
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00425386
- Testing
- erlotinib hydrochloride, sunitinib malate, biopsy
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
Renal Cell Carcinoma, Kidney Cancer
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).
- Trial name
- NCT02687139
- Testing
- 18F-DCFPyL, PET/CT
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Johns Hopkins University
Renal Cell Carcinoma
Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Metastatic renal cell carcinoma (mRCC) is the most common malignant tumour of the kidneys. Targeted therapies, which were recently introduced in the treatment of mRCC, have become the standard treatment in these patients.
- Trial name
- NCT02315755
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Pfizer
Kidney Cancer, Leukemia
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
RATIONALE: Glutamine may help lessen neuropathy caused by chemotherapy. It is not yet known whether glutamine is more effective than a placebo in treating neuropathy caused by vincristine.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity
- Trial name
- NCT00365768
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Columbia University
Lymphoma, Childhood Lymphoma
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life.
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor
- Trial name
- UVA-Gen001 (NCT02624388)
- Testing
- Genistein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Virginia
Cervical, Ovarian
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
Background: Some cancer cells have a large amount of a protein called P-glycoprotein, which can pump certain chemotherapy drugs out of their cells.
- Conditions
- Cervical, Ovarian, Lung, Breast
- Trial name
- NCT00972205
- Testing
- paclitaxel, CBT-1(Registered Trademark), Tc 99m sestamibi
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)